| Bid | 5.9 |
| Market Cap | 357.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -4.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6 |
| Volume | 978,738 |
| Avg. Volume (20D) | 550,649 |
| Open | 6.56 |
| Previous Close | 6.49 |
| Day's Range | 5.84 - 6.60 |
| 52-Week Range | 5.42 - 11.05 |
| Beta | undefined |
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable...
Analyst Forecast
According to 11 analyst ratings, the average rating for HCAT stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 87.23% from the latest price.
Next Earnings Release
Analysts project revenue of $80.57M, reflecting a 7.31% YoY growth and earnings per share of 0.08, making a 300.00% increase YoY.
4 weeks ago · seekingalpha.com
Health Catalyst: Improved Demand Environment Reinforces My Buy RatingDespite positive demand and fundamentals, I believe the market undervalues HCAT's growth potential. Gross margin contraction is due to temporary headwinds, which should ease, leading to strong margin ...
